Author:
Rice Adrian,Verma Mohit,Shin Annie,Zakin Lise,Sieling Peter,Tanaka Shiho,Balint Joseph,Dinkins Kyle,Adisetiyo Helty,Morimoto Brett,Higashide Wendy,Anders Olson C.,Mody Shivani,Spilman Patricia,Gabitzsch Elizabeth,Safrit Jeffrey T.,Rabizadeh Shahrooz,Niazi Kayvan,Soon-Shiong Patrick
Abstract
AbstractWe have developed a COVID-19 vaccine, hAd5 S-Fusion + N-ETSD, that expresses SARS-CoV-2 spike (S) and nucleocapsid (N) proteins with modifications to increase immune responses delivered using a human adenovirus serotype 5 (hAd5) platform. Here, we demonstrate subcutaneous (SC) prime and SC boost vaccination of CD-1 mice with this dual-antigen vaccine elicits T-helper cell 1 (Th1) biased T-cell and humoral responses to both S and N that are greater than those seen with hAd5 S wild type delivering only unmodified S. We then compared SC to intranasal (IN) prime vaccination with SC or IN boosts and show that an IN prime with an IN boost is as effective at generating Th1 biased humoral responses as the other combinations tested, but an SC prime with an IN or SC boost elicits greater T cell responses. Finally, we used a combined SC plus IN (SC + IN) prime with or without a boost and found the SC + IN prime alone to be as effective in generating humoral and T-cell responses as the SC + IN prime with a boost. The finding that SC + IN prime-only delivery has the potential to provide broad immunity—including mucosal immunity—against SARS-CoV-2 supports further testing of this vaccine and delivery approach in animal models of viral challenge.
Publisher
Springer Science and Business Media LLC
Reference62 articles.
1. Sieling, P., King, T., Wong, R., Nguyen, A., Wnuk, K., Gabitzsch, E., Rice, A., Adisetiyo, H., Hermreck, M., Verma, M. et al. Single prime hAd5 Spike (S) + nucleocapsid (N) dual antigen vaccination of healthy volunteers induces a ten-fold increase in mean S- and N- T-cell responses equivalent to T-cell responses from patients previously infected with SARS-CoV-2. medRxiv 2021:2021.2004.2005.21254940.
2. Amalfitano, A., Begy, C. R. & Chamberlain, J. S. Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors. Proc. Natl. Acad. Sci. U.S.A. 93(8), 3352–3356 (1996).
3. Amalfitano, A. et al. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J. Virol. 72(2), 926 (1998).
4. Hodges, B. L. et al. Multiply deleted [E1, polymerase-, and pTP-] adenovirus vector persists despite deletion of the preterminal protein. J. Gene Med. 2(4), 250–259 (2000).
5. Seregin, S. S. & Amalfitano, A. Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors. Expert Opin. Biol. Ther. 9(12), 1521–1531 (2009).
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献